Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mahnaz Darvish-Damavandi
Observed names:
Damavandi Mahnaz Darvish,
Darvish-Damavandi, Mahnaz,
M. Darvish Damavandi,
Mahnaz D. Damavandi,
Mahnaz Darvish Damavandi
Observed institutions:
Institute of Cancer Research,
National University of Singapore,
Wellcome/MRC Cambridge Stem Cell Institute,
University of Cambridge,
University of Oxford,
Pharmaceutical Sciences Research Center,
Tehran University of Medical Sciences
show all 7
ORCID:
0000-0003-0226-2621
Observed ORCID:
0000-0003-0226-2621
OpenAlex ID:
A5047306273
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
2018
·
Georgios Vlachogiannis
, Somaieh Hedayat
, et al.
·
Science
·
2,071
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
2022
·
Teresa Brevini
, Mailis Maes
, et al.
·
Nature
·
294
PDF
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial
2018
·
Khurum H. Khan
, David Cunningham
, et al.
·
Cancer Discovery
·
225
A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome
2010
·
Mahnaz Darvish-Damavandi
·
World Journal of Gastroenterology
·
89
PDF
Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study
2017
·
Khurum Khan
, Mihaela Rata
, et al.
·
Gut
·
72
PDF
miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial
2019
·
Gayathri Anandappa
, Andrea Lampis
, et al.
·
Clinical Cancer Research
·
49
PDF
Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1
2023
·
Callum Beach
, David MacLean
, et al.
·
Journal of Clinical Investigation
·
36
PDF
Targeting Acid Ceramidase to Improve the Radiosensitivity of Rectal Cancer
2020
·
Rachael E. Clifford
, Naren Govindarajah
, et al.
·
Cells
·
28
PDF
Towards the development of an enzyme replacement therapy for the metabolic disorder propionic acidemia
2016
·
Mahnaz Darvish-Damavandi
, Han Kiat Ho
, et al.
·
Molecular Genetics and Metabolism Reports
·
14
PDF
Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1
2024
·
Callum Beach
, David MacLean
, et al.
·
Journal of Clinical Investigation
·
4
PDF
FXR inhibition reduces ACE2 expression, SARS-CoV-2 infection and may improve COVID-19 outcome
2021
·
Teresa Brevini
, Mailis Maes
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
4
PDF
Development of an UPLC–MS/MS Method for Assaying The Enzymatic Activity of Propionyl Coenzyme-A Carboxylase
2014
·
Mahnaz Darvish Damavandi
, Eric Chun Yong Chan
, et al.
·
Bioanalysis
·
4
Cancer Stem Cells
2022
·
Mahnaz D. Damavandi
, Yi Zhou
, et al.
·
Elsevier eBooks
·
3
An analysis of SARS-CoV-2 cell entry genes identifies the intestine and colorectal cancer as susceptible tissues
2020
·
Mahnaz Darvish-Damavandi
, James Laycock
, et al.
·
British journal of surgery
·
3
PDF
Innate immune receptor C5aR1 regulates cancer cell fate and can be targeted to improve radiotherapy in tumours with immunosuppressive microenvironments
2023
·
Callum Beach
, David MacLean
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
1
PDF
O07 FXR antagonists as new agents for COVID19
2021
·
Teresa Brevini
, Mailis Maes
, et al.
·
1
PDF
Abstract 3589: Validation of the role of circulating tumor DNA (ctDNA) in tracking mechanisms of resistance to anti-EGFR monoclonal antibodies (AE-mABs): preliminary results of the PROSPECT-C prospective trial
2015
·
Khurum Khan
, George Vlachogianis
, et al.
·
Cancer Research
·
1
665: Targeting C5aR1 to improve radiotherapy in tumours with immunosuppressive microenvironments
2024
·
Callum Beach
, David MacLean
, et al.
·
Radiotherapy and Oncology
Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1
2023
·
Beach, Callum
, MacLean, David
, et al.
·
Zurich Open Repository and Archive (University of Zurich)
Supplementary Data from Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial
2023
·
Khurum H. Khan
, David Cunningham
, et al.
Supplementary Tables from Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial
2023
·
Khurum H. Khan
, David Cunningham
, et al.
Supplementary Table S4 from Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial
2023
·
Khurum H. Khan
, David Cunningham
, et al.
Supplementary Table S4 from Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial
2023
·
Khurum H. Khan
, David Cunningham
, et al.
Supplementary Tables from Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial
2023
·
Khurum H. Khan
, David Cunningham
, et al.
Supplementary Data from Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial
2023
·
Khurum H. Khan
, David Cunningham
, et al.
Show more works
View as search
Works count:
33
Citation count:
2,896
H-index:
9
I10-index:
9
Year
Topic
Type
